Ivan Suner, MD
Ophthalmology · Tampa, FLNPI 1164522793
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Genentech USA, Inc. at 40.5% of the total. Reporting peaked in 2022 at $91,264 and has fallen 62.5% since, to $34,204 in 2025. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 526 payments — averaging $718.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$153K
- Apellis Pharmaceuticals, Inc.$107K
- Regeneron Healthcare Solutions, Inc.$56K
- Novartis$18K
- Regeneron$10K
- Ocular Therapeutix, Inc.$7K
- plus $27K from 29 others
Across 534 payments — averaging $6351.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$3.1M
- Apellis Pharmaceuticals, Inc.$109K
- Novartis$88K
- Ocular Therapeutix, Inc.$33K
- Eyepoint US, Inc.$33K
- Alimera Sciences, Inc.$31K
- plus $22K from 4 others
What the payments were for
- Consulting fees$107,23428%
- Speaking & faculty fees$213,72057%
- Travel & lodging$33,8509%
- Food & beverage$23,1466%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 167 | $152,987 |
| Apellis Pharmaceuticals, Inc. | 79 | $106,767 |
| Regeneron Healthcare Solutions, Inc. | 62 | $55,632 |
| Novartis | 26 | $17,808 |
| Regeneron | 28 | $10,322 |
| Ocular Therapeutix, Inc. | 19 | $6,969 |
| AbbVie(2 entities) | 20 | $5,363 |
| Bausch & Lomb Americas Inc. | 20 | $4,462 |
| Astellas Pharma US Inc | 8 | $3,292 |
| Genentech, Inc. | 5 | $2,507 |
| ANI Pharmaceuticals, Inc. | 2 | $2,153 |
| Eyepoint US, Inc. | 9 | $2,086 |
| F. Hoffmann-la Roche AG | 2 | $1,722 |
| Thrombogenics, Inc. | 1 | $1,250 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 14 | $830 |
| Alimera Sciences, Inc. | 20 | $785 |
| Amgen | 5 | $564 |
| Harrow Eye, LLC | 6 | $468 |
| Alcon | 4 | $325 |
| Notal Vision, Inc. | 2 | $323 |
| Coherus Oncology, Inc. | 6 | $227 |
| Sight Sciences, Inc. | 1 | $149 |
| NEW World Medical,inc. | 1 | $142 |
| Sandoz | 5 | $137 |
| Biogen | 3 | $133 |
| Immunocore Limited | 1 | $125 |
| Dompe US, Inc. | 1 | $122 |
| Cardinal Health 108 LLC | 1 | $75 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Sun Pharmaceutical Industries Inc. | 2 | $47 |
| Samsara Vision | 1 | $32 |
| Kala Pharmaceuticals, Inc. | 1 | $23 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $22 |
| Astellas Pharma Global Development | 1 | $16 |
| Oyster Point Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$377,951 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 30 | $10,716 |
| Prednisolone Acetate | 97 | $3,924 |
| Difluprednate | 16 | $1,696 |
| MoxifloxacinMoxifloxacin Hcl | 62 | $1,359 |
| Atropine Sulfate | 27 | $902 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 51 | $735 |
| Brimonidine Tartrate | 29 | $727 |
| Timolol Maleate | 47 | $373 |
| Dorzolamide Hcl | 17 | $279 |
| Latanoprost | 43 | $213 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan | $5,363 | $10,71630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Tampa
- Courtney BoveeTampa$796K
- Pedram HamrahTampa$187K
- Thomas NewsomTampa$186K
- Don PerezTampa$178K
- Brian SzaboTampa$86K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.